Baxter International Inc (NYSE:BAX) SVP Jacqueline Kunzler sold 5,934 shares of the company’s stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $88.12, for a total value of $522,904.08. Following the completion of the transaction, the senior vice president now directly owns 3,089 shares in the company, valued at approximately $272,202.68. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Jacqueline Kunzler also recently made the following trade(s):
- On Wednesday, June 19th, Jacqueline Kunzler sold 593 shares of Baxter International stock. The shares were sold at an average price of $80.46, for a total value of $47,712.78.
BAX stock traded up $1.90 during mid-day trading on Friday, reaching $89.81. The company had a trading volume of 280,580 shares, compared to its average volume of 1,976,535. The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.10 and a current ratio of 2.78. The company has a market capitalization of $45.30 billion, a price-to-earnings ratio of 29.44, a price-to-earnings-growth ratio of 2.03 and a beta of 1.00. The firm has a fifty day simple moving average of $85.70 and a 200 day simple moving average of $79.67. Baxter International Inc has a fifty-two week low of $61.05 and a fifty-two week high of $88.48.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, October 1st. Shareholders of record on Friday, August 30th will be given a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a yield of 0.98%. The ex-dividend date of this dividend is Thursday, August 29th. Baxter International’s dividend payout ratio is currently 28.85%.
A number of hedge funds have recently bought and sold shares of the business. BlackRock Inc. raised its position in Baxter International by 1.4% in the 2nd quarter. BlackRock Inc. now owns 40,589,288 shares of the medical instruments supplier’s stock valued at $3,324,263,000 after purchasing an additional 560,814 shares in the last quarter. Morgan Stanley increased its holdings in shares of Baxter International by 5.5% in the 2nd quarter. Morgan Stanley now owns 17,154,303 shares of the medical instruments supplier’s stock valued at $1,404,937,000 after acquiring an additional 895,279 shares during the last quarter. Northern Trust Corp increased its holdings in shares of Baxter International by 0.6% in the 2nd quarter. Northern Trust Corp now owns 8,758,537 shares of the medical instruments supplier’s stock valued at $717,323,000 after acquiring an additional 54,889 shares during the last quarter. Veritas Asset Management LLP increased its holdings in shares of Baxter International by 0.5% in the 2nd quarter. Veritas Asset Management LLP now owns 7,886,549 shares of the medical instruments supplier’s stock valued at $645,908,000 after acquiring an additional 35,600 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Baxter International by 4.8% in the 4th quarter. Geode Capital Management LLC now owns 6,444,204 shares of the medical instruments supplier’s stock valued at $423,409,000 after acquiring an additional 297,006 shares during the last quarter. 82.60% of the stock is currently owned by institutional investors.
BAX has been the topic of several recent analyst reports. Zacks Investment Research raised Baxter International from a “hold” rating to a “buy” rating and set a $86.00 price target on the stock in a research note on Friday, June 21st. Barclays set a $82.00 price target on Baxter International and gave the company a “hold” rating in a research note on Friday, July 26th. Credit Suisse Group upped their price target on Baxter International from $84.00 to $95.00 and gave the company an “outperform” rating in a research note on Friday, July 26th. JPMorgan Chase & Co. upped their price target on Baxter International from $80.00 to $88.00 and gave the company an “overweight” rating in a research note on Monday, May 13th. Finally, Raymond James upped their price target on Baxter International from $84.00 to $95.00 and gave the company an “outperform” rating in a research note on Friday, July 26th. Four equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $85.27.
Baxter International Company Profile
Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Featured Article: What is the role of the G-20?
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.